Breakthrough in Treating Liver Cancer with Combination Therapy

Strategic Insights -

Research conducted by Sichuan University and published in Frontiers in Immunology has demonstrated the efficacy of combining stereotactic body radiotherapy (SBRT) with immunotherapy in treating metastatic hepatocellular carcinoma (HCC). In a case study, a patient with HBV-related advanced HCC achieved significant progression-free survival and overall survival with the combination treatment. This innovative approach shows promise in treating patients who have resistance to traditional treatments.

Key Takeaways:

  • A 10-month progression-free survival and 21-month overall survival were achieved in a patient with HBV-related metastatic HCC using a combination of anti-PD-1 therapy and SBRT as third-line treatment.
  • The combination therapy demonstrated relative efficacy and favorability in treating HBV-related advanced HCC.
  • The patient's response to treatment, known as an abscopal effect, was observed, indicating that the tumor microenvironment was reprogrammed and converted from "cold" to "hot" tumors.
  • The study highlights the potential of combining radiotherapy with immunotherapy to improve treatment outcomes for patients with advanced HCC.
  • The research is a collaborative effort between Sichuan University and the Cancer Center, West China Hospital, and was supported by the National Natural Science Foundation of China.

Statistics:

  • The patient achieved a 10-month progression-free survival and 21-month overall survival with the combination treatment.
  • The study included a single patient case report with HBV-related metastatic HCC.
  • The treatment involved a combination of anti-PD-1 therapy and SBRT, administered as third-line treatment.
  • The patient's response to treatment is an example of an abscopal effect, which is a rare phenomenon where the tumor microenvironment is reprogrammed and converted from "cold" to "hot" tumors.
  • The study was conducted by Sichuan University, with Yu Pei as the primary author, and was published in Frontiers in Immunology.

Sources:

  • Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor. Frontiers in Immunology, 2025,16.
  • Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology
  • The publisher for Frontiers in Immunology is Frontiers Media S.A.